Rivoceranib FDA Approval Status
Last updated by Judith Stewart, BPharm on Oct 6, 2024.
FDA Approved: No
Generic name: rivoceranib
Company: Elevar Therapeutics, Inc.
Treatment for: Hepatocellular Carcinoma
Rivoceranib is an oral tyrosine kinase inhibitor (TKI) in development for the treatment of hepatocellular carcinoma.
- Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
- Rivoceranib works in the treatment of solid tumors by inhibiting VEGF-induced endothelial cell migration and proliferation, and thus inhibiting the angiogenesis essential for tumor growth and survival.
- Clinical studies for rivoceranib are in progress for multiple solid tumor indications including unresectable hepatocellular carcinoma (in combination with camrelizumab), gastric cancer (as a monotherapy and in combination with paclitaxel), adenoid cystic carcinoma (as a monotherapy), and colorectal cancer (in combination with Lonsurf®).
Development timeline for rivoceranib
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.